Expert Statement: Jordi Robinson, Navin Molecular
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Interview
Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ludwig de Mot, EuroAPI
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Frank Wegener, ESIM Chemicals
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Russel Miller, Enzene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: David McErlane and Aris Gennadios, Catalent
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ashu Tandon, Aragen
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gavin Murdoch, Abzena
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Using Chemistry to Create Net-Zero Value Chains
In this interview, Charlie Tan, CEO of the Global Impact Coalition (GIC), explains the initiative’s scope and describes some key activities.
Trying Times and a Wave of Light
In February, industry leaders from 20 industrial sectors presented the ‘Antwerp Declaration for a European Industrial Deal’. The declaration emphasizes industry's dedication to Europe's transformation and outlines urgent needs to enhance Europe's competitiveness, resilience, and sustainability amid challenging economic circumstances.
Formulating Innovative Concepts
Matthias Hofmann, Group Innovation & Technology Management Director at Azelis, provides an in-depth insight into the company’s innovation activities and the underlying market trends.
Innovation Through Formulation
Anna Bertona, Group CEO at Azelis, looks back on her first six month in this role and gives an insight into her plans for the company's development.
Sustainable Practices in Biopharmaceuticals
BioPhorum, an industry collaboration group, focuses on advancing sustainability within the biopharmaceutical sector. In an exclusive interview, Nicola Coles, Director of BioPhorum Sustainability, shares insights into the organization’s commitment to environmentally responsible practices.
At the Cutting Edge of Catalysis Innovation
In this interview, Phillip Chalabi, Umicore’s director Strategic Projects and Innovation, gives an overview of the company’s activities in precious metal chemistry.
A New Standard of Collaboration for the Pharmaceutical Industry
Headquartered in Cramlington, UK, Sterling Pharma Solutions is a contract development and manufacturing organization (CDMO) that provides a range of services to the global biopharmaceutical industry, including active pharmaceutical ingredient (API) development, scale-up and cGMP manufacturing, as well as antibody drug conjugate (ADC) R&D and clinical-scale GMP manufacturing.
Noncanonical Amino Acids Made by Enzymes
Aralez Bio, a San Francisco-based start-up, has engineered a platform of enzymes that creates 100 times more compound diversity using processes that are also 50 times greener than conventional methods.
High Dynamics in the Supply Chain
Interview with Markus Mau, President of the ELA, about developments for the logistics sector.
Chemical Distributor Creates Opportunities Through Innovation
On January 1, 2024, Anna Bertona will take on the role of Group CEO, succeeding Hans Joachim Müller, who will retire after serving more than 11 years in that role. Ralf Kempf asked Müller and Bertona about the foundations for the group's continued success and plans for its future strategic direction.
The Chemical Distribution Industry
Lars Wallstein, IMCD’s Managing Director Germany, who was elected in September as President of FECC – the European Association of Chemical Distributors. He discusses current market trends and the organization's vision for the future of the sector.
Unleashing Sustainable Innovation, Navigating Business, and Pioneering a Greener Future
In today’s world, where environmental sustainability is at the forefront of global concerns, green chemistry stands as a beacon of hope. This field focuses on inventing sustainable solutions that mitigate the harmful impact of traditional chemical processes.
Substitution of Biocides in Cooling Water Treatment
The Heidelberg-based start-up Blue Activity replaces 100% of biocides in cooling water treatment with natural, functional microorganisms. The product change increases the efficiency of cooling tower performance and reduces water consumption and operating costs.
Accelerate Chemical and Material Development
Process manufacturing companies waste almost $100 billion globally every year while formulating novel materials and chemicals due to the trial-and-error approach to R&D and the lack of tools to leverage the experimental data in real-time.
The Green Power of Catalysis
With more than 80% of all chemical products manufactured using catalytic processes, catalysts are the number one value generator in the chemical industry.
